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A B S T R A C T
Purpose
To investigate the prognostic and predictive significance of subtyping node-positive early breast
cancer by immunohistochemistry in a clinical trial of a docetaxel-containing regimen.
Methods
Pathologic data from a central laboratory were available for 1,350 patients (91%) from the BCIRG
001 trial of docetaxel, doxorubicin, and cyclophosphamide (TAC) versus fluorouracil, doxoru-
bicin, and cyclophosphamide (FAC) for operable node-positive breast cancer. Patients were
classified by tumor characteristics as (1) triple negative (estrogen receptor [ER]–negative,
progesterone receptor [PR]–negative, HER2/neu [HER2]–negative), (2) HER2 (HER2-positive,
ER-negative, PR-negative), (3) luminal B (ER-positive and/or PR-positive and either HER2-positive
and/or Ki67high), and (4) luminal A (ER-positive and/or PR-positive and not HER2-positive or
Ki67high), and assessed for prognostic significance and response to adjuvant chemotherapy.
Results
Patients were subdivided into triple negative (14.5%), HER2 (8.5%), luminal B (61.1%), and
luminal A (15.9%). Three-year disease-free survival (DFS) rates (P values with luminal B as
referent) were 67% (P .0001), 68% (P .0008), 82% (referent luminal B), and 91% (P .0027),
respectively, with hazard ratios of 2.22, 2.12, and 0.46. Improved 3-year DFS with TAC was found
in the luminal B group (P  .025) and a combined ER-positive/HER2-negative group treated with
tamoxifen (P  .041), with a marginal trend in the triple negatives (P  .051) and HER2 (P  .068)
subtypes. No DFS advantage was seen in the luminal A population.
Conclusion
A simple immunopanel can divide breast cancers into biologic subtypes with strong prognostic
effects. TAC significantly complements endocrine therapy in patients with luminal B subtype and,
in the absence of targeted therapy, is effective in the triple-negative population.
J Clin Oncol 27:1168-1176. © 2009 by American Society of Clinical Oncology
INTRODUCTION
There has been a steady evolution in the adjuvant
treatment of early breast cancer. In patients with
hormone-sensitive tumors, tamoxifen reduces the
risk of recurrence and death by more than 30%.1
Subsequently, anthracycline-based chemotherapy1
and, more recently, taxane-containing regimens,2
have been shown to be most efficacious in improv-
ing disease-free (DFS) and overall survival (OS) in
patients with operable node-positive breast cancer.
Since the study of Perou et al3 using gene ex-
pression studies to identify discrete genetic subtypes
of breast cancer with distinct prognoses, there has
been a paradigm shift in adjuvant therapy decisions,
away fromrisk categories basedon stage alone to the
determination of tumor responsiveness.4 This mo-
lecular advance has been difficult to translate into
current clinical practice because a number of highly
significant but nonoverlapping gene signatureswith
prognostic effect have been proposed,5-9 complicat-
ing their application, and because the large clinical
trials that inform current evidenced-based treat-
ment decisions generally do not have available ma-
terials suitable for gene expression profile-based
molecular subtyping.
Subsequent work has shown that although the
genetic definitions may vary across classification
schemes, most of these systems will classify tumors
intocategorieswith similar clinical implications.10,11
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The primary molecular subdivision is by estrogen receptor (ER) sta-
tus,3,8,12 with further subdivision of ER-positive tumors into luminal
A and a worse-prognosis luminal B category. The ER-negative
tumors are subdivided into HER2/neu (HER2)–positive and a
basal-like group, the latter being approximated by a triple negative
(ER-negative, progesterone receptor [PR]–negative, HER2-negative)
phenotype.13 Themost significant discriminator in the subset assign-
ment of ER-positive tumors is proliferation.14-16 Recent examination
of357 invasivebreast cancers subtypedbygeneexpressionanalysishas
determinedandvalidatedanoptimal cutpoint for aKi67proliferation
index to distinguish luminal B from luminal A (Cheang et al, manu-
script submitted for publication), suggesting that a simple immuno-
panel of ER, PR,HER2, andKi67 can serve as a proxy formuch of the
clinically relevant information generated by genetic subtyping.
In this unplanned, subset analysis of the Breast Cancer Interna-
tional Research Group (BCIRG) 001 trial, immunohistochemically
defined subsets of patients were examined to test the prognostic and
predictive significance of these subsets in a clinical trial setting.
Table 1. Patient Characteristics for the Total Study Population and Biologic Subtypes With Univariate Analysis of Disease-Free Survival in the Total Population
Characteristic No. Total HR P
Triple Negative HER2 Luminal B Luminal A
No. % No. % No. % No. %
Age, years
 50 711 1.00 — 111 58 53 47 450 56 84 40
50 639 0.88 .2449 81 42 60 53 360 44 127 60
Menopausal status
Pre 531 1.00 — 83 43 50 44 293 36 97 46
Post 819 0.90 .3362 109 57 63 56 517 64 114 54
Tumor size, cm
 2 576 1.00 — 67 35 45 40 347 43 107 51
 2 774 1.61  .0001 125 65 68 60 463 57 104 49
Histologic subtype
Lobular 286 1.00 — 6 3 3 3 183 23 90 43
Ductal other 1064 1.72 .0003 186 97 110 97 627 77 121 57
Overall histologic grade
1 245 1.00 — 1 1 1 1 131 16 108 52
2 603 1.96 .0007 26 14 37 33 436 54 96 46
3 489 3.54  .0001 163 86 75 66 236 29 4 2
Vascular invasion
None/minimal 938 1.00 — 132 70 71 68 557 72 164 85
Extensive 338 1.60  .0001 56 30 33 32 213 28 29 15
Positive lymph nodes
1-3 903 1.00 — 129 68 74 66 550 69 131 64
4-9 327 1.81  .0001 50 26 30 27 189 24 54 26
10 103 2.79  .0001 12 6 8 7 62 8 20 10
Estrogen receptor
Negative 318 1.00 — 192 100 113 100 3 0 3 1
Positive 1021 0.52  .0001 0 0 0 0 807 100 208 99
Progesterone receptor
Negative 498 1.00 — 192 100 113 100 156 19 29 14
Positive 841 0.50  .0001 0 0 0 0 654 81 182 86
HER2
Negative 1034 1.00 — 192 100 0 0 626 78 211 100
Positive 288 1.56 .0002 0 0 113 100 175 22 0 0
Ki67-1 index
Low 242 1.00 — 5 3 5 4 14 2 211 100
High 1099 1.85 .0002 187 97 108 96 796 98 0 0
p53 staining
Negative 1014 1.00 — 96 50 56 50 650 81 200 95
Positive 320 1.52 .0003 96 50 56 50 155 19 11 5
Treatment
FAC 663 1.00 — 90 48 57 50 397 49 107 51
TAC 679 0.73 .0027 99 52 56 50 408 51 104 49
Tamoxifen
No 442 1.00 — 167 87 94 83 139 17 30 14
Yes 908 0.43  .0001 25 13 19 17 671 83 181 86
Abbreviations: HR, hazard ratio; FAC, fluorouracil, doxorubicin, cyclophosphamide; TAC, docetaxel, doxorubicin, cyclophosphamide.
HER2 status was determined using fluorescent in situ hybridization (1,264 patients) or CB11 (53 patients for whom fluorescent in situ hybridization results were
not available).
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METHODS
Patients
BCIRG 001 was a multicenter, prospective, randomized, phase III trial
comparing docetaxel, doxorubicin, and cyclophosphamide (TAC) with
fluorouracil,doxorubicin,andcyclophosphamide(FAC)asadjuvantchem-
otherapy in 1,491 women with operable, node-positive breast cancer. A rep-
resentative tumor sample in the formof formalin-fixed paraffin blocks and/or
diagnostic histologic slides was available for 1,350 patients (91%). Other data,
including baseline characteristics of the patients and clinical outcomes, were
extracted from the BCIRG database used for the second interim analysis of
survival (median, 55 months of follow-up), results of which have been previ-
ously reported.2 All patients provided informed consent. The trial protocol
was approved by the research ethics board of the Alberta Cancer Board.
Immunohistochemical and Fluorescent In Situ Hybridization
Analysis of Tissue Specimens
Slide review, immunohistochemistry, andfluorescence in situhybridiza-
tion (FISH) assays were performed in a central laboratory and read by one
pathologist (J.H.). Automated slide processing platforms (Ventana Medical
Systems, Tucson, AZ) were used for both immunohistochemical and FISH
assays. Representative unstained tumor specimens were stained for ER (clone
6F11, Ventana), PR (clone 636; Dako, Carpinteria, CA), HER2 (clone CB11,
Ventana), Ki67 (cloneMIB-1, Dako), and p53 (clone 1801; Novocastra Labo-
ratories Ltd,Newcastle uponTyne,UnitedKingdom). Immunohistochemical
datawere recordedas thepercentageofpositive cells andgrade1 to3 (greatest)
staining intensity. The FISH assay for HER2 was performed according to the
manufacturer’s instructions (PathVysion; Abbott Molecular Inc, Des Plaines,
IL). Tumorswere classified as ER- or PR-positive if stainingwas present in 1%
ormore of tumor nuclei and p53 positive if more than 10% of nuclei stained.
The Ki67 cut point of 13% established by Cheang et al (Cheang et al, manu-
script submitted for publication) was used to designate a tumor as high
proliferation. For HER2, either intense staining (3) or a HER2:Cep17 ratio
greater than 2.2 were regarded as positive for immunohistochemical analysis
or FISH, respectively.17
Statistical Analysis
All data generated during central review were recorded in the BCIRG
database. A randomsample of 500 cases (hematoxylin-eosin and immunohis-
tochemistry samples) were reviewed by Ian Ellis (Nottingham, United King-
dom). For histologic grade and ER status, there was complete agreement in
69% and 85% of cases, with  values of 0.56 (moderate) and 0.87 (almost
perfect), respectively. The level of agreement for histologic grade was consis-
tent with that of published studies.18,19 In addition, the concordance rate for
theFISHresultswas97%(29of30)withanexternal laboratory (MichaelPress,
Los Angeles, CA) on nonstudy cases.
The occurrence of a DFS event, defined as relapse, second primary
malignancy, or death, was the primary outcome and was analyzed for each
prognostic variable. Univariate and multivariate analyses were performed
using the SAS phreg procedure (SAS Institute, Cary, NC) for the Cox regres-
sion model for survival. The SAS lifetest procedure was used to calculate
Kaplan-Meier probability estimates for DFS and OS. The SAS logistic proce-
durewasused toobtain significance levelswithodds ratios (ORs) and95%CIs
for 3-year DFS rates analysis and histologic tumor type, tumor size, extent of
vascular invasion, tumor grade, proliferation index, and p53 by biologic sub-
type relative to the most common subtype in this study cohort, luminal B.
Univariate Cox regression analysis was performed for each prognostic
variable. Subsequently, those variables that were not used in the computation
of thebiologic subtypesandyieldedaunivariate resultofP .10were included
in themultivariatemodel.MultivariateCox regressionanalysiswasperformed
using the stepwise backward elimination method with model removal set at
P  .10. The multivariate model included as primary prognostic variables
biologic subtype andchemoendocrine treatment (TAC,FAC, and tamoxifen),
with interaction terms for tamoxifen treatment and biologic subtype. Tumor
grade, primary tumor size, extent of vascular invasion, andnumber of positive
lymph nodes were added as covariables.
The results are presented in accordance with reporting recommenda-
tions for tumormarker prognostic studies criteria.20
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Fig 1. Disease-free and overall survival among patients according to biologic subtype. (A) Disease-free survival and (B) overall survival for patients stratified into
triple-negative (estrogen receptor [ER] negative, progesterone receptor [PR] negative, HER2/neu [HER2] negative), HER2 (HER2-positive, ER-negative, PR-negative),
luminal B (LB; ER-positive or PR-positive and either HER2-positive or Ki67high) and luminal A (LA; ER-positive or PR-positive and not HER2-positive or Ki67high) groups.
Pairwise comparisons between subtypes were statistically significant (see text).
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RESULTS
The frequency of the clinicopathologic variables in the total popula-
tion are presented in Table 1. On univariate analysis, a significant
prognostic effect was detected for tumor size; histologic subtype; tu-
mor grade; extent of vascular invasion; nodal involvement; hormone
receptor status; expression of HER2, Ki67, and p53; chemotherapy;
and tamoxifen treatment, with increases in hazard ratios (HRs) for
recurrence associated with increases in tumor size and number of
positive nodes. No statistically significant prognostic effect was found
for age or menopausal status.
We were able to classify the study population into four breast
cancer subtypes (Table 1): triple negative (ER-negative, PR-negative,
HER2-negative), HER2 (ER-negative, PR-negative, HER2-positive),
luminal B (ER-positive and/or PR-positive and either HER2-positive
and/or Ki67high), and luminal A (ER-positive and/or PR-positive and
notHER2-positive or Ki67high). These subtypes accounted for 14.5%,
8.5%, 61.1%, and 15.9%, respectively. Twenty-four (1.8%) were un-
assigned, primarily because of missing HER2 values owing to insuffi-
cient tumormaterial or nonformalin fixation.
The biologic subtypes were prognostically significant for DFS
and OS (Fig 1). The 3-year DFS rates, HR, and P values for pairwise
comparison with luminal B were 67% (HR 2.22; 95% CI, 1.56 to
3.16; P .0001) for triple negative, 68% (HR  2.12; 95% CI, 1.37
to 3.29; P .0008) for HER2, 82% (referent) for luminal B, and 91%
(HR  0.46; 95% CI, 0.28 to 0.77; P  .0027) for luminal A. The
triple-negative and HER2 groups had a similarly poor prognosis
(P .788), as has been described.14
A multivariate analysis, which excluded variables defining the
subtypes (ER, PR, HER2, Ki67), identified independent significance
for treatment with TAC/FAC, treatment with tamoxifen, size more
than 2 cm, grade 3, extensive vascular invasion, number of involved
lymph nodes, treatment, and biologic subtypes (Table 2).
ORs for the association of biologic subtype with prognostic tu-
mor characteristics are shown in Table 3, with the most common
subtype, luminal B, as the referent group. Compared with luminal B,
the triple-negative and HER2 subtypes were more likely to have a
ductal histogenesis (OR 9.2; 95%CI, 4.00 to 21.04; P .0001; and
OR 10.6, 95% CI, 3.33 to 33.85; P .0001, respectively), whereas
luminal A cases were more likely to have nonductal disease (eg,
lobular or mixed ductal-lobular histogenesis, OR  0.4; 95% CI,
0.27 to 0.52; P .0001). Patientswith the luminalA subtypewere less
likely tohave tumors larger than2cm(OR0.7; 95%CI, 0.54 to0.99;
P .05), extensive vascular invasion (OR 0.5; 95%CI, 0.30 to 0.71;
P .0004), grade 3 (OR 0.05; 95%CI, 0.02 to 0.13; P .0001), or
p53 positivity (OR  0.2; 95% CI, 0.12 to 0.43; P  .0001). p53
positivity was more frequent in the triple-negative (OR 4.19; 95%
CI, 3.01 to 5.85; P .0001) and HER2 (OR 4.19; 95% CI, 2.78 to
Table 2. Stepwise Multivariate Analysis of Disease-Free Survival
for All Cases and for Luminal A and Luminal B
Characteristic
Hazard
Ratio 95% CI P
All cases
TAC treatment 0.73 0.58 to 0.91 .0051
Tamoxifen treatment 0.41 0.31 to 0.56  .0001
Tamoxifen triple negative 4.01 2.00 to 8.05  .0001
Tamoxifen HER2 2.56 0.95 to 6.93 .0633
Tamoxifen luminal A 0.56 0.34 to 0.93 .0257
Triple negative 0.62 0.43 to 0.90 .0124
HER2 0.65 0.42 to 1.02 .0602
Tumor size  2 cm 1.33 1.05 to 1.69 .0178
Histologic subtype 1.39 0.99 to 1.96 .0612
Grade 3 1.39 1.07 to 1.80 .0137
Vascular invasion 1.34 1.06 to 1.69 .0141
4-9 positive nodes 1.87 1.46 to 2.40  .0001
10 positive nodes 3.09 2.23 to 4.27  .0001
Luminal B
TAC treatment 0.71 0.53 to 0.95 .022
Tamoxifen treatment 0.44 0.32 to 0.61  .0001
Tumor size  2 cm 1.49 1.10 to 2.02 .011
Histologic subtype 1.62 1.06 to 2.49 .027
1-3 positive nodes 1.98 1.46 to 2.67  .0001
4-9 positive nodes 1.61 1.15 to 2.26 .005
10 positive nodes 4.33 2.93 to 6.41  .0001
Luminal A
TAC treatment 0.97 0.46 to 2.06 .943
Tamoxifen treatment 0.15 0.07 to 0.33  .0001
4-9 positive nodes 4.30 1.81 to 10.20 .001
10 positive nodes 5.11 1.82 to 14.37 .002
NOTE. Variables involved in the definition of biologic subtypes were not
included in this model.
Abbreviation: TAC, docetaxel, doxorubicin, cyclophosphamide.
Table 3. Odds Ratios for Patient and Tumor Characteristics by Biologic Subtype
Variable Category
Triple Negative HER2
Luminal B (referent)
Luminal A
OR P OR P OR P
N1 v N2
Type, ductal v lobular 9.17  .0001 10.61  .0001 1.0 0.38  .0001
Size,  2 v  2 cm 1.40 .0450 1.13 .5436 1.0 0.73 .0408
Grade, 1 v 2 0.13 .0447 0.09 .018 1.0 3.74  .0001
Grade, 3 v 1  2 14.50  .0001 4.74  .0001 1.0 0.05  .0001
Vascular invasion, positive v negative 1.11 .5612 1.22 .3871 1.0 0.46 .0004
MIB-1 index, high v low 1.52 .4270 2.63 .0683 1.0 NA
p53, positive v negative 4.19  .0001 4.19  .0001 1.0 0.23  .0001
PR, positive v negative NA NA 1.0 1.50 .0655
Abbreviations: OR, odds ratio; NA, not applicable; PR, progesterone receptor.
Includes lobular mixed and pure lobular carcinomas.
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6.32; P  .0001) groups, compared with luminal B. Patients with
triple-negative tumors had the greatest likelihood of having grade 3
tumors (OR 14.5; 95%CI, 9.39 to 22.40; P .0001).
Comparedwith patients in the luminal B group, the hazard ratio
for a DFS event in patients in the luminal A group was significantly
decreased for tumor sizemore than 2 cm (HR 0.47; 95%CI, 0.28 to
0.79; P  .0042), moderate (HR  0.46; 95% CI, 0.23 to 0.91;
P .027) and high (HR 0.54; 95%CI, 0.33 to 0.87; P .012) levels
of ER expression, as well as in the subgroupwith one to three positive
nodes (HR 0.37; 95%CI, 0.19 to 0.70; P .002).
Nineteen percent and 14% of patients in the luminal B and
luminal A groups, respectively, were negative for PR. A multivariate
analysis controlling for the presence of PR showed a persistent signif-
icant difference between luminal A and luminal B (HR 0.46; 95%
CI, 0.29 to0.74;P .0014), excludingdifferences inPRas thebasis for
differences between the subtypes in patients treated with tamoxifen.
Patients in the luminal B group showed a statistically significant
improvement in DFS favoring the taxane arm, with 3-year DFS of
85.2% versus 79% (HR 0.66; 95% CI, 0.46 to 0.95; P .025) for
TACandFAC, respectively (Fig 2). Therewasmarginal significance in
the triple-negative andHER2 subtypes, with 3-yearDFSof 73.5%and
60.0% (HR 0.50; 95% CI, 0.29 to 1.00; P .051) and 76.4% and
60.3% (HR 0.46; 95%CI, 0.20 to 1.06; P .068) for TAC and FAC
in the respective subtypes. There was no difference between chemo-
therapy regimens in patients in the luminal A group: 92.2% and
89.3%, respectively (HR 0.70; 95%CI, 0.27 to 1.83; P .472).
Although the trial protocol specified adjuvant tamoxifen after
chemotherapy for all ER-positive patients, 5%did not receive tamox-
ifen for a variety of reasons and an additional 11% of patients had a
negative agreementbetween the central laboratory and theoriginating
laboratory, such that 17% of patients in the luminal B and 14% of
patients in the luminalAgroupswerenot treatedwith tamoxifen.This
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Fig 2. Disease-free survival (DFS) among patients treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) or docetaxel, doxorubicin, and cyclophospha-
mide (TAC) according to biologic subtype. Disease-free survival is shown in patients classified as (A) triple negative, (B) HER2, (C) luminal B, or (D) luminal A treated
with FAC or TAC. P values in each panel are logistic regression calculations based on 3-year DFS. ER, estrogen receptor; PR, progesterone receptor.
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magnitude of negative agreement is similar to that reported in the
Eastern Cooperative Oncology 2197 trial21 and is a well-described
phenomenon in interlaboratory testing.22,23 When tamoxifen treat-
ment was entered into the multivariate Cox and DFS model, signifi-
cant interactions were found, with biologic subtype indicating that
subgroup analysis was appropriate. There were few patients treated
with tamoxifen in the triple-negative (13%) and HER2 (17%) sub-
types, and there was no significant effect of tamoxifen treatment in
these groups (P .3), so the interaction in these groups is not consid-
ered further. The multivariate analysis for luminal A and luminal B
subtypes is presented in Table 2. Both the luminal A and luminal B
subtypes showed significant responses to tamoxifen, with HR 0.44
(95%CI, 0.32 to 0.61; P .0001) for luminal B andHR 0.15 (95%
CI, 0.07 to 0.33; P  .0001) for luminal A. As in the unadjusted
comparisons, when patients were treated with tamoxifen, TAC was
superior to FAC in patients in the luminal B group, with a 3-yearDFS
of 89.4% and 82%, respectively (HR  0.71; 95% CI, 0.53 to 0.95;
P  .02, multivariate model) and not in patients in the luminal A
group,with a 3-yearDFSof 93%and96.6%(HR0.97; 95%CI, 0.46
to 2.06; P .90, multivariate model; Fig 3).
We performed an exploratory analysis similar to a recently pub-
lished24 examination of the response of ER-positive/HER2-positive
and ER-positive/HER2-negative patients to adjuvant taxane chemo-
therapy. As in that study, log-rank P values are provided as ameasure
ofdiscordanceandshouldbeviewedasdescriptive,not inferential.We
found that TAC was associated with improved DFS among the ER-
positive/HER2-positive patients (Fig 4A), with similar trends seen in
both the tamoxifen-treated and untreated patients (Fig 4B). Contrary
to that study, in the ER-positive/HER2-negative patients who had
receivedtamoxifen, therewasabenefittothetaxane-containingchem-
otherapy arm (Fig 4D). This advantage was not seen in those patients
who did not receive tamoxifen (Fig 4D), nor in the unsegregated
population (Fig 4C).
DISCUSSION
It is now accepted that breast cancer is heterogeneous at a molecular
level.4There is increasingevidence that thesemolecular subtypesdiffer
in their response to therapeutic agents.14,16,25 Our results build on
these findings and indicate that patients with ER-negative tumors
(both triple-negative andHER2) show a better response to TAC than
to FAC, with the difference in response to the taxane regimen being
marginally statistically significant. Despite this response, these sub-
types have a worseDFS andOS, with themajority of events occurring
early. This is consistent with neoadjuvant reports that document in-
creased chemosensitivity in these subtypes, but poor outcome as a
result of higher and faster relapse among those with residual dis-
ease.16,25 It is expected that if trastuzumab had been included in this
early protocol, the 3-year recurrence risk would have been halved in
the HER2 population.26
The triple-negative phenotype used in this study only approxi-
mates thebasal-like subtype,27 although theprofileof theDFS14,27 and
phenotypic characteristics (eg, predominantly ductal [97%], grade 3
[86%], p53 abnormal [50%] with a high proliferation index [97%])
are in keepingwith characteristics of the basal subtype.28,29 The basal-
like subtype itself is heterogeneous and encompasses the majority of
BRCA1-related carcinomas, medullary carcinomas, and metaplastic
carcinomas13 and is overrepresented in the aggressive tumors seen in
premenopausal African Americans.30,31 Although this heterogeneity
can theoretically alter chemosensitivity,31 we were not able to further
define subgroups within this subtype to investigate that possibility.
Theuseof a simpleproliferation index results in ahighly effective
separation of ER-positive patients into two intrinsically different pop-
ulations, luminal A and luminal B (Cheang et al, manuscript submit-
ted forpublication).11,14-16,32 These subtypeshave adifferentoutcome
when compared across tumor size, nodal status, and level of estrogen
or progesterone receptor positivity. This underscores the importance
of proliferation and supports suggestions that incorporation of a pro-
liferation score into therapy decisions may complement11 or even
supplant16,33histologicgrade.Assignmentofbiologic subtypewithout
considerationofhistologic type resulted in significant separation,with
the triple-negative andHER2 groups being almost exclusively of duc-
tal origin. Approximately one half of the luminal A subtype consisted
of lobular and mixed ductal-lobular carcinomas, consistent with evi-
dence supporting a close genetic relationship between low-grade duc-
tal carcinoma and lobular carcinomas.34,35
In patients treated with tamoxifen, patients in the luminal B but
not luminal A group show a significant benefit of TAC over FAC
chemotherapy. The benefit of taxanes in hormone receptor–positive
tumors is controversial.36 Analysis of first-generation taxane trials in
adjuvant therapy including the Grupo Espanol de Investigacion del
Cancer deMama 990637 and a pooled analysis of this present trial and
PACS0138 found no statistically significant interaction between hor-
mone receptor status and taxane response, with benefit in both the
ER-positive and ER-negative patients. However, subset analyses of
two other taxane trials, the E219739 and the Cancer and Leukemia
Group B (CALGB),24,40 as well as neoadjuvant data,16,41 suggest that
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Fig 3. Forest plot of covariate adjusted hazard ratios (HR) for disease-free
survival in patients in the luminal A and luminal B groups by treatment (hazard
ratios and 95% CIs using fluorouracil, doxorubicin, and cyclophosphamide and no
tamoxifen as baseline treatments). Values less than 1 show an advantage to
docetaxel, doxorubicin, and cyclophosphamide (TAC) or tamoxifen.
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the response to taxanes is less in ER-positive compared with ER-
negative tumors. Our results show that the benefit of the addition of
taxanes to tamoxifen is restricted to the luminal B population, and
because this group comprises the majority of ER-positive patients in
this study, this benefit is probably responsible for the positive effect of
TAC in the tamoxifen-treated ER-positive/HER2-negative (Fig 4D)
and in the ungrouped ER-positive patients.38 The patients in the
luminal A group show no benefit to docetaxel when added to
tamoxifen (Fig 3), a finding that is not surprising given that tax-
anes’ stabilization of microtubules and mitotic arrest42 would be
expected to preferentially target rapidly dividing cells. Of note,
subset analysis of the PACS 01 trial, presented in abstract form,
also found that a “luminal” subtype, defined as ER-positive and
basal-like subtype parameters–negative, showed no difference in
response to the addition of docetaxel.43
These findings parallel the experience in node-negative patients.
Currently, large cooperative trials in North America (Trial Assigning
Individualized Options for Treatment)44 and Europe (Microarray in
Node-Negative Disease May Avoid Chemotherapy45 and Node Neg-
ative Breast Cancer46) are studying the integration of genomic or
biochemical profiles into decisions concerning the necessity of adding
chemotherapy tohormonal therapy in selectedgroupsofpatientswith
hormone receptor–positive disease.
In the ER-positive/HER2-negative patients treated with tamox-
ifen, there was a significant benefit to the taxane regimen (Fig 4D).
This differs from the analysis of a similar subset in the CALGB 9344/
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Fig 4. Disease-free survival among estrogen receptor positive patients treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) or docetaxel, doxorubicin,
and cyclophosphamide (TAC) according to HER2 status and tamoxifen (Tamox) treatment. Disease-free survival for estrogen receptor (central lab)–positive patients,
(A) positive or (C) negative for HER2, by treatment arm. (B, D) Subdivision of these patients by tamoxifen treatment. Log-rank P values are descriptive only.
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INTO148 trial of patients with node-positive breast cancer treated
with doxorubicin plus cyclophosphamide, followed by paclitaxel or
observation.24 In that report, there was no benefit to the addition of
paclitaxel in a similar group of patients. Cross-trial comparisons are
difficult, but possible reasons for this difference include superior per-
formance of docetaxel to the paclitaxel dosing protocol used in that
trial,47,48 or alternatively, there may have been a greater admixture of
patients with low-proliferative luminal A disease in the CALGB
subset, thus diluting the effect of the taxane in the unsegregated
ER-positive population.
The high risk of recurrence in ER-positive tumors not treated
with tamoxifen is similar to that reported in the subset analysis by
Berry et al40 and is in keeping with themeta-analysis results1 showing
that themajorbenefit in adjuvant therapy in theER-positive tumors is
due to tamoxifen. This suggests that the prognostic effect seen with
molecular subdivision is due in large part to its ability to predict
response to treatments optimized to each subtype, rather than differ-
ing metastatic potential between the subtypes. In this regard, our
results show that TAC significantly complements endocrine therapy
in tamoxifen-treatedpatients in the luminalB group, analogous to the
improved outcomes in HER2-positive patients treated with doxoru-
bicin andcyclophosphamide followedbydocetaxelwith trastuzumab.
In the absence of specific targeted therapy, TAC is also effective in the
triple-negative population. Because this is a retrospective, unplanned
subset analysis without adjustment for multiple comparisons, these
findings, although consistent with existing literature, should be re-
garded as hypothesis generating.
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